Exposure to phthalates found in many household products can lower women’s ability to conceive

USA: A recent study published in Environmental Health Perspectives has revealed a link between exposure to phthalates and a lower probability of getting pregnant, but not pregnancy loss. Phthalates are a group of plasticizing and solvent chemicals found in many household products such as shampoo, makeup, vinyl flooring, toys and medical devices.

The study also noted an association between preconception exposure to phthalates and changes in women’s reproductive hormones, as well as increased inflammation and oxidative stress.

“Phthalates are ubiquitous endocrine disruptors and we’re exposed to them every day,” says lead author Carrie Nobles, assistant professor of environmental health sciences in the School of Public Health and Health Sciences.

People are exposed primarily by ingesting food and liquid that has come in contact with products containing the chemicals, according to a Centers for Disease Control and Prevention fact sheet.

Nobles and team analyzed data from a “unique cohort” of women in the preconception time-to-pregnancy study known as EAGeR (Effects of Aspirin in Gestation and Reproduction), which evaluated the effect of low-dose aspirin on live-birth rates.

The study includes detailed information on 1,228 participants during six menstrual cycles when they are attempting to get pregnant.

The women who became pregnant were followed through pregnancy.

“We were able to look at some environmental exposures like phthalates and how that relates to how long it takes to get pregnant. There was detailed data for each menstrual cycle, so we had a good handle on the date of ovulation and the timing of pregnancy when that happened,” Nobles says.

The body breaks down phthalates into metabolites that are excreted in urine and can be analyzed.

The researchers measured 20 phthalate metabolites in urine samples taken when the participants enrolled in the study.

“We found there were three parent compounds that seem to be most strongly associated with taking longer to get pregnant, although we saw a general trend toward it taking longer to get pregnant across the phthalates we looked at,” Nobles says.

“As exposure got higher, we saw more and more of an effect.”

The researchers also looked at a global marker of inflammation, C-reactive protein, and found the women who had higher levels of phthalates exposure also had higher levels of inflammation and oxidative stress, which can lead to organ and tissue damage and ultimately to disease.

In addition, women who showed higher levels of phthalates had lower estradiol and higher follicle-stimulating hormone across the menstrual cycle, which play an important role in ovulation and the early establishment of pregnancy.

“This profile — estradiol staying low and follicle-stimulating hormone staying high — is actually something that we see in women who have ovarian insufficiency, which can happen with age as well as due to some other factors,” Nobles says.

“Ovulation just isn’t happening as well as it used to.”

While women can check consumer product labels and look for phthalate-free options, the ubiquitous nature of the chemicals makes it difficult for an individual to control their exposure.

In Europe, certain phthalates are banned or severely restricted in their use, but the U.S. has no formal prohibitions.

Nobles says the research findings add to the evidence that phthalate exposures harm women’s reproductive health and can be used to help inform policymaking.

“Maybe we want to think differently about our regulatory system and how we identify important exposures that are having adverse effects on whether people can get pregnant and have a healthy pregnancy,” Nobles says.

Reference:

Carrie J. Nobles, Pauline Mendola, Keewan Kim, Anna Z. Pollack, Sunni L. Mumford, Neil J. Perkins, Robert M. Silver, Enrique F. Schisterman. Preconception Phthalate Exposure and Women’s Reproductive Health: Pregnancy, Pregnancy Loss, and Underlying Mechanisms. Environmental Health Perspectives, 2023; 131 (12) DOI: 10.1289/EHP12287

Powered by WPeMatico

Synokem Pharmaceutical Gets CDSCO Panel Nod To study Antidiabetic FDC Drug

New Delhi: With the condition of including more government sites distributed geographically, Synokem Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical trial of the fixed-dose combination of the antidiabetic drug Linagliptin plus Metformin Hydrochloride film-coated bilayered tablet.

This recommendation came after Synokem Pharmaceutical presented the Phase IV clinical trial protocol before the committee, in light of the condition mentioned in permission in Form CT-23 dated 24.04.2023.

Linagliptin is a medicine used to treat type 2 diabetes. Type 2 diabetes is a condition where the body does not make enough insulin, or the insulin that it makes does not work properly. This can cause high blood sugar levels (hyperglycemia).

Linagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Metformin is an oral anti-diabetic drug in the biguanide class for the treatment of type 2 diabetes mellitus, in particular, in overweight and obese people and those with normal kidney function. Metformin is a medicine used to treat type 2 diabetes and gestational diabetes.

At the recent SEC meeting for Endocrinology and Metabolism held on 23 November 2023, the expert panel reviewed the Phase IV clinical trial protocol of the FDC antidiabetic drug Linagliptin plus Metformin Hydrochloride film-coated bilayered tablet presented by Synokem Pharmaceutical.

After detailed deliberation, the committee recommended a grant of permission to conduct the Phase IV clinical trial with the condition to include more government sites, which should be geographically distributed.

In addition, the expert panel suggested that the firm should submit the Phase IV clinical trial report to CDSCO for further review by the committee.

Also Read: Akum Pharmaceutical Gets CDSCO Panel Nod to Manufacture, Market Azelnidipine, Metoprolol FDC tablet

Powered by WPeMatico

Patient’s death case at GMCH Chandigarh: No medical negligence, says hospital panel

Chandigarh: Investigating the allegations of medical negligence in the case of a 63-year-old woman who had suffered a cardiac arrest due to a pending MRI test and its related treatments, which was believed to have potentially saved her life, the committee has found no substantial evidence against the doctor or the Government Medical College and Hospital (GMCH), Sector 32.

According to the preliminary report submitted by the panel, the doctor was not deemed negligent since there was insufficient evidence implicating him or the hospital in any misconduct that could have resulted in medical negligence and the patient’s demise.

This comes in response to the allegations made by the deceased’s family members, accusing the doctor of providing inadequate healthcare services and delaying treatment to the patient. They alleged that rather than sending the COVID samples to a private institution, GMCH should have taken charge of conducting the tests and administering the appropriate treatment to the patient. 

Also read- Doctors Cannot Be Blamed For Consequences Of Pre-Existing Conditions: Consumer Court Relief To Orthopaedic Surgeon, Hospital

Denying the claims, Hospital director-principal Dr Jasbinder Kaur informed HT, “The medical negligence committee has concluded that there is no substantial evidence which proves that the treating doctor has any monetary consideration for getting laboratory test from a private lab. Further, as per statements given by the doctors and careful examination of the complaint, along with documentary evidence placed on record, the committee thinks that the patient was managed properly as per protocol,” 

According to The Daily, the case involved a 63-year-old woman from Baltana, Mohali, who was admitted to the hospital on May 8, 2021, during the peak time of the COVID-19 pandemic. She was experiencing pain in the upper limbs. 

The medical examination revealed that she was diabetic and had no blood flow in the arteries, causing extreme pain in the right upper limb. The doctors planned an embolectomy (removal of a blood clot) to relieve the thrombus and resume blood flow.

Due to the strict protocol during the peak of the COVID-19 pandemic, all surgery/ICU/MRI patients were required to undergo RTPCR testing. However, due to the high volume of tests, it took more than 24 hours to test patients within GMCH. The RTCPR test was done through a private laboratory after discussing with the patient’s attendants to prioritise patient care.

The medical negligence committee in the report stated that the test samples were sent to a GMCH lab and a private hospital. The private hospital’s report was negative for Covid. Although the report was available before the MRI, the test could not be done as the patient was developing breathlessness. 

On May 11, the patient was moved to a ventilator after severe chest pain and falling unconscious. Despite efforts, including CPR, the patient suffered a cardiac arrest and was subsequently moved to the ICU. Another cardiac arrest occurred on May 13, and despite all measures, the patient could not be revived.   

The GMCH officials decided to engage the police in the matter, consequently submitting the report to the Chandigarh SSP for necessary measures to be taken.

Also read- No Medical Negligence Or Mistake In Diagnosis: SC Dismisses Plea Against Indraprastha Apollo Hospital, Neurosurgeon

Powered by WPeMatico

Union Home Minister promises to decriminalize medical negligence deaths

In an unprecedented move, Union Home Minister Amit Shah has promised in the Parliament to decriminalise deaths due to medical negligence by doctors, drawing a big cheer from the entire medical fraternity.

Addressing the Lok Sabha, the Home Minister stated, “Currently, if there is a death due to negligence of a doctor, it is also treated as criminal negligence, almost akin to murder. Hence, I will bring an official amendment now to free the doctors from this criminal negligence.”

For more details, check out the link given below:

Breaking News: Home Minister Amit Shah Promises To Decriminalize Medical Negligence Deaths

Powered by WPeMatico

UK Junior Doctors on 3-day strike over pay dispute

London: Junior doctors in Britain started a three-day strike in their long-standing dispute with the government over pay and conditions. 

Junior doctors — around half of all doctors in the National Health Service (NHS) — took strike action from 7 a.m. local time on Wednesday until Saturday morning. Further strikes, starting from January 3 next year and lasting six days, have also been announced and would be the longest in the history of the NHS.

The NHS warned on its website that, although other doctors will still be working, “the disruption to staffing will cause a significant reduction in elective activity,” leading to the rescheduling of some appointments and procedures.

Also Read:UK Junior and Senior doctors to go on 4-day joint strike over pay dispute

“On strike days, accident and emergency departments and NHS 111 (digital triage service) are likely to be extremely busy, with longer waiting times than normal,” the NHS added.

Junior doctors’ pay has been cut by more than a quarter since 2008, according to the British Medical Association (BMA). They have been calling for a 35 per cent pay increase amid Britain’s ongoing cost-of-living crisis, Xinhua news agency reported.

In recent talks, doctors were offered an additional three per cent raise on top of the 8.8 per cent pay increase recommended, but the BMA said it would be unevenly spread across doctors’ grades so it would still amount to pay cuts for many doctors this year.

Chancellor of the Exchequer Jeremy Hunt called the strikes “incredibly disappointing” in an interview, adding that Health and Social Care Secretary Victoria Atkins “has said her door is open for constructive discussions”.

Five organisations, including the NHS Confederation and the Patients Association, wrote an open letter, calling on both the government and the BMA to “get back to the negotiating table,” and “find a resolution and bring an end to their dispute”.

Caroline Abrahams from a charity in the UK called Age UK said that the ongoing and upcoming strikes, occurring during “the busiest time of the year in the NHS,” may pose “a much greater potential threat to older people’s health and well-being”.

According to Age UK, more than 1.2 million operations and appointments were cancelled throughout 2023, and waiting lists increased by 510,000 from January to 7.71 million in October.

Widespread strikes in Britain started in the summer of 2022 amid disputes over pay and working conditions. The majority of the strikes were in the health, social work and education sectors.

Powered by WPeMatico

USFDA declines to approve Merck chronic cough drug Gefapixant

New Jersey: The U.S. Food and Drug Administration (FDA) declined to approve Merck’s drug for chronic cough, the company said on Wednesday, marking the second rejection in less than two years.

The health regulator concluded the company’s application for the drug, gefapixant, did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic cough.

Currently, there are no approved treatments in the United States for coughing bouts that don’t go away despite treatment of underlying conditions or have no identifiable cause.

The condition is estimated to affect up to 13% of the global adult population.

In November, the agency’s advisory committee panel voted 12 to 1 against the late-stage data submitted for gefapixant, on concerns over how well it works.

The FDA’s decision was not related to the drug’s safety, Merck said, adding that it is reviewing the agency’s feedback to determine next steps.

Failing to secure marketing approval the first time, Merck carried out additional efficacy analyses of the drug to address questions raised by the health regulator. The results from the additional analyses were generally consistent with those from the late-stage trial, Merck said.

The FDA’s decision gives some breathing room to rival GSK’s chronic cough treatment camlipixant, which is in late-stage development with anticipated regulatory approval and launch in 2026.

Merck’s gefapixant works by blocking receptors that stimulate the nerves and trigger the urge to cough.

The drug, which was given twice a day, was evaluated across two late-stage trials where a higher dose showed statistically significant reduction in the average number of coughs per hour over a 24-hour period compared to a placebo, according to Merck.

The European Union and Japan have approved Merck’s drug for the condition and it is sold under the brand name Lyfnua.

Read also: Merck bags USFDA nod for Keytruda, Padcev combo for urothelial cancer

Powered by WPeMatico

Evergreen Talk Series: Linagliptin and Dapagliflozin combination for T2DM with Cardiovascular risk or established ASCVD

Presenting the Evergreen Talk Series featuring Dr. Brij Mohan
Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr. Sameer I.
Dani, an Interventional Cardiologist from Ahmedabad, and Dr. Tukaram Jamale, a
Nephrologist and Kidney Transplant Physician who serves as the Head of the
Department at KEM Hospital Mumbai. They provide their insights on the use of
Linagliptin, Dapagliflozin, and Metformin for diabetic patients.

Bringing viewpoints from the different specialities of
Diabetology, Cardiology and Nephrology they share the clinical benefits of the
Linagliptin and Dapagliflozin combination for T2DM with Cardiovascular risk or
established ASCVD.

Dr Brij Mohan Makkar: When Linagliptin and Dapagliflozin are combined, Linagliptin
demonstrates cardiovascular safety, hepatic safety, renal safety, no risk of
hypoglycemia, and no weight gain. It acts indirectly on insulin secretion and
suppresses glucagon. SGLT2 inhibitors are useful in reducing mortality in
people with established atherosclerotic cardiovascular disease, heart failure,
and advanced chronic kidney disease. Therefore, using this combination of
molecules in people with established atherosclerotic cardiovascular disease or
those at high risk is the recommended choice according to almost every
guideline now.

Dr Sameer I Dani: Linagliptin and Dapagliflozin both have established evidence or
a record of cardiovascular safety. Both have enough evidence for cardiorenal
safety. These medicines belong to two different classes of drugs and complement
each other. They have different mechanisms of action, different pathways of
metabolism, and that’s how they complement each other without causing drug
interactions. So, the chances of drug-drug interactions are very low. Both
agents have cardiovascular outcome benefits, making the combination use very
logical.

Dr Tukaram Jamale: One of the important reasons that patient discontinues or
decrease the dosages of the drug is cost and the pill burden. Patients at
elevated ASCVD risks stand to benefit the most from these drugs individually.
Therefore, a combination approach serves the purpose of making the treatment
available at a substantially lower cost and reduces the number of pills to be
consumed in a day.

Powered by WPeMatico

Assam govt releases budget for eight new medical colleges

Guwahati: In a significant development, the state government has released a budget for eight medical colleges as part of its plan to establish 21 medical colleges in Assam by 2026-2027. 

Currently, Assam boasts a total of 12 medical colleges. However, the government is actively engaged in the development of an additional 9 medical colleges, with plans to complete four more of them by 2026-27. It is important to note that the budget has only been allocated for 8 out of the proposed 12 medical colleges.

The 12 medical colleges, that are still in the pipeline, include Tinsukia Medical College, Biswanath Medical College, Charaideo Medical College, Pragyotishpur Medical College, Morigaon Medical College, Dhemaji Medical College, Bongaigaon Medical College, Golaghat Medical College, Tamulpur Medical College and Hospital, Sibsagar Medical College, Karimganj Medical College and Goalpara Medical College.

Also read- NMC Grants Recognition To 2 Assam Medical Colleges

The budget released for the eight medical colleges- Tinsukia will receive funding of Rs 614.933 crore, Charaideo with Rs 500 crore funding, Biswanath with Rs 500 crore funding, Tamulpur with Rs 666.935 crore funding, Dhemaji with Rs 605.248 crore funding, Bongaigaon with Rs 610.674 crore funding, Morigaon with Rs 647.375 crore funding, and Golaghat with Rs 631.823 crore funding.

Meanwhile, the funding for three proposed medical colleges in Sibsagar, Goalpara, and Karimganj has not yet been finalized. However, the proposed Pragjyotishpur Medical College in Guwahati will be funded through corporate social responsibility.

Earlier, Chief Minister Himanta Biswa Sarma said that the construction of Tinsukia Medical College will be completed this year and medical colleges at Charideo and Biswanath Chariali will be dedicated to the service of the people by next year.

Medical Dialogues team had previously reported where the Minister said that the number of medical colleges in Assam will increase to 21 by 2026-27.

“The inauguration of the first-year courses of Nagaon, Nalbari and Kokrajhar medical colleges has marked the beginning of a new era in medical education in Assam. Prime Minister Narendra Modi inaugurated the medical colleges of Nagaon, Nalbari and Kokrajhar on April 14 this year along with AIIMS in Changsari, which were constructed with an expenditure of Rs. 1,800 crore,” he said.

“Before 2010, there were only three medical colleges in Assam. Jorhat Medical College was inaugurated in 2010 and five medical colleges were established during the last decade. Last year Dhubri Medical College was opened and today academic sessions of Nagaon, Nalbari and Kokrajhar medical colleges have been started,” the Chief Minister added.

The Chief Minister said that in 2014, the number of MBBS seats in Assam was 726. Whereas now it has stood at 1,500 with the increase in the number of medical colleges.

As per the Hitavada news report, there are plans for seven new nursing colleges in Diphu, Lakhimpur, Dhubri, Nagaon, Kokrajhar, Jorhat, and Nalbari. The nursing colleges in Diphu, Lakhimpur, Dhubri, Nagaon, and Kokrajhar will be located within the respective medical colleges. The necessary funds have already been released for these colleges, and the State Public Works Department has prepared detailed project reports. 

The nursing colleges in Jorhat and Nalbari will be constructed at Rs 10 crore under the North Eastern Council. Furthermore, there are proposals for two more dental colleges in Lakhimpur and Morigaon.

Also read- By 2026-27, Assam Will Have 21 Medical Colleges: CM Himanta Biswa Sarma

Powered by WPeMatico

Maternal Height Independent Risk of Adverse Outcomes in Women with Gestational Diabetes

A recent retrospective study conducted by Mengkai Du and colleagues from Zhejiang University in Hangzhou, China, shed light on a vital aspect of maternal health: the correlation between maternal height and adverse pregnancy outcomes in women diagnosed with gestational diabetes mellitus (GDM). The investigation delved into how this association varied concerning gestational weight gain (GWG) and pre-pregnancy body mass index (BMI).

The study was published in the journal of Diabetes Therapy by Mengkai Du and colleagues. The study, encompassing 2048 women diagnosed with GDM between July 2017 and June 2018 in Zhejiang Province, China, presented intriguing observations. The researchers discovered that shorter stature in women with GDM was associated with higher rates of low birth weight (LBW) (p = 0.003) and primary cesarean section (primary CS) (p < 0.001). Conversely, taller women with GDM exhibited elevated rates of abnormal neonatal ponderal index (p < 0.001), postpartum hemorrhage (p = 0.044), and macrosomia (p < 0.001).

The investigators highlighted the importance of considering gestational weight gain and pre-pregnancy BMI as independent factors influencing pregnancy outcomes. They noted that shorter women with pre-pregnancy obese BMI faced a substantially higher risk of macrosomia compared to shorter women with normal or overweight pre-pregnancy BMI.

During the study, maternal height was categorized into three groups: shorter (≤158 cm), average (between 158.1 – 162.0 cm), and taller (>162.0 cm). Notably, shorter women experienced higher rates of low birth weight (LBW) (p = 0.003) and primary cesarean section (primary CS) (p < 0.001), while taller women had increased instances of abnormal neonatal ponderal index (p < 0.001), postpartum hemorrhage (p = 0.044), and macrosomia (p < 0.001).

Further analysis revealed intriguing correlations based on gestational weight gain and pre-pregnancy BMI. For instance, shorter women with inadequate gestational weight gain showed a significant association between maternal height and low birth weight (aOR 2.20, 95% CI 1.13–4.29), while taller women with excess weight gain demonstrated a positive link between maternal height and the risk of macrosomia (aOR 1.97, 95% CI 0.95–4.10).

The study’s findings underscore the pivotal role of maternal height in predicting adverse outcomes in women with gestational diabetes mellitus. Importantly, the researchers emphasized the necessity of considering pre-pregnancy BMI and gestational weight gain when assessing the impact of maternal height on pregnancy outcomes. This approach could aid in identifying women at high risk of complications and facilitate personalized prenatal care strategies.

Reference:

Du, M., Muhuza, M. P. U., Tang, Y., Chen, Y., Chen, D., Zhang, L., & Liang, Z. Maternal height is an independent risk of adverse outcomes in women with gestational diabetes mellitus. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders,2023. https://doi.org/10.1007/s13300-023-01512-3

Powered by WPeMatico

First comprehensive medical guideline on management of pouchitis released

The American Gastroenterological Association (AGA) has released the first comprehensive evidence-based guideline on the management of pouchitis, the most common complication people with ulcerative colitis experience following surgery to remove their colon.

Between 150,000 and 300,000 people with ulcerative colitis in the U.S. live with a surgically created internal reservoir or “pouch” created from their small intestine as an alternate way to store and pass stool after their diseased colon is removed. The pouch can become inflamed, a condition called pouchitis, which affects almost half of patients within two years of surgery and up to 80% of patients over time.

“As providers we struggle to get insurance approval for medications to treat pouchitis, because it has not been a well-defined or recognized entity. Our intention with this guideline is to help improve access for patients and providers to use these advanced therapies,” said guideline author Siddharth Singh, MD, MS, University of California, San Diego.

AGA provides the following guidance for physicians caring for patients with ulcerative colitis who undergo proctocolectomy with ileal pouch-anal anastomosis, also known as IPAA or J-pouch.

  • AGA suggests initial treatment of pouchitis with antibiotics.

  • Treatment with multi-strain probiotics following an antibiotic course is suggested for preventing recurrent pouchitis.

  • AGA suggests cyclical or near continuous antibiotic therapy to treat pouchitis that responds to antibiotics but recurs frequently and shortly after antibiotics are discontinued.

  • In patients with recurrent pouchitis that doesn’t respond to antibiotics or Crohn’s-like disease of the pouch, AGA suggests advanced immunosuppressive medications (ie. Infliximab, vedolizumab, ustekinumab, upadacitinib, etc.)

Pouchitis has a significant impact on patients’ quality of life, so there is interest in ways to prevent it from occurring. The AGA guideline suggests against use of antibiotics for primary prevention of pouchitis, and guideline authors did not find enough scientific evidence to recommend for or against the use of probiotics for prevention.

AGA outlines four types of inflammatory pouch disorders

Intermittent pouchitis

  • This happens when a patient experiences infrequent episodes of pouchitis symptoms that get better with treatment.

Chronic antibiotic-dependent pouchitis

  • This occurs when a patient’s pouchitis responds to antibiotics, but symptoms quickly return after antibiotics are stopped (typically within days to weeks).

Chronic antibiotic-refractory pouchitis

  • This occurs when patients experience continuous symptoms of pouchitis that don’t get better with antibiotic therapy. Patients usually require more advanced treatment such as steroids or immunosuppressive medication.

Crohn’s-like disease of the pouch

  • Patients may have issues like fistulas (abnormal passages), strictures (narrowing) and inflammation in the small intestine above the pouch.

Amber Tresca, a patient advocate who has been living with a J-pouch for over 20 years shares that, “it’s important for patients to know how to care for their pouch if they develop pouchitis, especially if they don’t have access to a healthcare provider that is a pouch specialist. This guideline can help patients understand that pouchitis is a real condition, there is treatment for it, and that they don’t have to live with symptoms.”

Reference:

Edward L. Barnes, Manasi Agrawal, Gaurav Syal, Laura E. Raffals, Siddharth Singh, AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders, DOI:https://doi.org/10.1053/j.gastro.2023.10.015.

Powered by WPeMatico